Cargando…
Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development
ARX788 is an anti-HER2 antibody drug conjugate (ADC) developed using Ambrx proprietary Engineered Precision Biologics technology. The manufacturing process of ARX788 has been optimized during the course of early to late-phase clinical development. A comprehensive evaluation of side-by-side comparabi...
Autores principales: | Yu, Wayne, Ramprasad, Mysore P., Pal, Manoj, Chen, Chris, Paruchuri, Shashi, Skidmore, Lillian, Knudsen, Nick, Allen, Molly, Buechler, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332591/ https://www.ncbi.nlm.nih.gov/pubmed/37428761 http://dx.doi.org/10.1371/journal.pone.0284198 |
Ejemplares similares
-
Phase 1 multicenter, dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma
por: Zhang, Yang, et al.
Publicado: (2022) -
788: Can we achieve low tidal volume ventilation in pregnant women with acute respiratory distress syndrome?
por: Paruchuri, Yasaswi, et al.
Publicado: (2018) -
Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs
por: Díaz-Rodríguez, Elena, et al.
Publicado: (2021) -
Basal ganglia involvement in ARX patients: The reason for ARX patients very specific grasping?
por: Curie, Aurore, et al.
Publicado: (2018) -
Posters P788 - P999
Publicado: (2005)